159752-10-0
159752-10-0
Chemical Structure
Ibutamoren Mesylate
Synonym(s): MK-677; MK-0677
- CAS. Nr.: 159752-10-0
- Formula:C28H40N4O8S2
- Molecular Weight:624.77
IUPAC Name: (R)-2-amino-N-(3-(benzyloxy)-1-(1-(methylsulfonyl)spiro[indoline-3,4'-piperidin]-1'-yl)-1-oxopropan-2-yl)-2-methylpropanamide methanesulfonate
InChIKey: DUGMCDWNXXFHDE-VZYDHVRKSA-N
SMILES: CC(N)(C(N[C@@H](C(N1CCC2(CN(C3=C2C=CC=C3)S(=O)(C)=O)CC1)=O)COCC4=CC=CC=C4)=O)C.CS(=O)(O)=O
Biological Activity: Ibutamoren Mesylate (MK-677) is a potent, non-peptide Growth hormone secretagogue receptor (GHSR) agonist. Ibutamoren Mesylate is an orally active growth hormone (GH) secretagogue.
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ibutamoren Mesylate | 99.86% | Ibutamoren Mesylate (MK-677) is a potent, non-peptide Growth hormone secretagogue receptor (GHSR) agonist. Ibutamoren Mesylate is an orally active growth hormone (GH) secretagogue. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ibutamoren | 99.84% | Ibutamoren (MK-677 free base; MK-0677 free base) is an orally active non-peptide growth hormone secretagogue receptor agonist. Ibutamoren activates signal cascades by mimicking endogenous ligands, triggers pulsatile release of growth hormone from the pituitary gland, and increases serum levels of IGF-1 and insulin-like growth factor-binding protein 3. Ibutamoren not only increases the frequency of growth hormone pulses in male individuals, but also promotes elevated bone formation markers in female individuals with postmenopausal osteoporosis. The combination of Ibutamoren with Alendronate sodium hydrate (HY-11101) significantly increases bone mineral density at the femoral neck. However, Ibutamoren may cause mild, reversible adverse reactions such as increased appetite, fluid retention, and elevated fasting blood glucose. Ibutamoren has been widely used in studies related to idiopathic growth hormone deficiency, sarcopenia, Alzheimer's disease, and osteoporosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Daglutril | Daglutril is a compound with the potential to regulate cytokine-induced endothelin-1 production in astrocytes. In studies, it has an inhibitory effect on the production of endothelin-1 induced by some cytokines and can be used as a tool to screen compounds that inhibit endothelin-1 production in astrocytes. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Endopeptidase-IN-1 | Endopeptidase-IN-1 serves as an inhibitor of endopeptidase activity. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-163255 free base | L-163255 free base is an orally active spiropiperidine GH secretagogue. L-163255 (free base) can also increase plasma IGF-I level. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Dihydro K22 | Dihydro K22 is a derivative of the antiviral agent K22 (HY-122668). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Difelikefalin | 99.95% | Difelikefalin (CR-845; FE-202845) is an orally active peripherally acting kappa opioid receptor agonist. Difelikefalin reduces acute kidney injury, decreases oliguria, maintains urine flow, inhibits cytokine expression, and improves survival in endotoxemia after ischemia/reperfusion. Difelikefalin suppresses pruritus signals and exhibits neuromodulatory antipruritic activity. Difelikefalin can be used in research related to acute kidney injury, chronic kidney disease-associated pruritus, and atopic dermatitis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Difelikefalin hydrochloride | Difelikefalin hydrochloride (CR-845 hydrochloride; FE-202845 hydrochloride) is an orally active peripherally acting kappa opioid receptor agonist. Difelikefalin hydrochloride reduces acute kidney injury, decreases oliguria, maintains urine flow, inhibits cytokine expression, and improves survival in endotoxemia after ischemia/reperfusion. Difelikefalin hydrochloride suppresses pruritus signals and exhibits neuromodulatory antipruritic activity. Difelikefalin hydrochloride can be used in research related to acute kidney injury, chronic kidney disease-associated pruritus, and atopic dermatitis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Riminkefon | Riminkefon is a kappa opioid receptor agonist. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Anrikefon | Anrikefon is a peripherally restricted kappa opioid receptor (KOR) agonist, with an IC50 of 0.54 nM, an EC50 of 2.41 pM, and a Ka of 0.068 nM against human KOR, and it exhibits high selectivity over μ and δ opioid receptors. Anrikefon exerts analgesic effects by inhibiting behaviors associated with inflammatory, postoperative and neuropathic pain, and also exerts antipruritic effects by reducing itch-related behaviors. Anrikefon can be used in research on pain, pruritus, and pruritus associated with chronic kidney disease. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Anrikefon acetate | 99.68% | Anrikefon (HSK21542) acetate is a kappa opioid receptor agonist with analgesic effect. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
